Response Genetics Expands Proprietary ResponseDX: Lung™ and ResponseDX: Colon™ Genetic Tests to Include Additional Patented Biomarkers Associated With Chemotherapy Response

Business Wire, April 30, 2009

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to expand its ResponseDX: Lung™ and ResponseDX: Colon™ tests , and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

1 The NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer (Version 2.2009). Available at: www.nccn.org. Accessed [4/23/09].

2 Cobo, M. Isla, D, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression; a phase III trial in non-small cell lung cancer. J Clin Oncol. 2007;25:2747-54.

3 Simon, G, Sharma, A, et al. Feasibility and efficacy of molecular analysis directed individualized therapy in advanced NSCLC. J Clin Oncol. 2007;25:2741-46.